Completed PHASE3 INTERVENTIONAL 2-arm NCT01302392

A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma (FOCUS)

A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma

Sponsor: Amgen

Conditions Multiple Myeloma

Interventions Best Supportive Care Carfilzomib

Updated 7 times since 2017 Last updated: Apr 28, 2017 Started: Sep 30, 2010 Primary completion: Jul 31, 2014 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01302392, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by Amgen, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2017 [monthly]

Completed PHASE3

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Arlon, Belgium , Athens, Greece , Barcelona, Spain , Belgrade, Serbia , Bratislava, Slovakia , Brno, Czechia , Bruges, Belgium , Brussels, Belgium , Budapest, Hungary and 58 more locations